Actively Recruiting
Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well
Led by Amrou Sarraj · Updated on 2026-04-06
408
Participants Needed
6
Research Sites
187 weeks
Total Duration
On this page
Sponsors
A
Amrou Sarraj
Lead Sponsor
P
Patient-Centered Outcomes Research Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
SELECT LATE trial aims to evaluate if addition of endovascular thrombectomy to medical management in patients presenting with acute ischemic stroke and a proximal large vessel occlusion in the anterior circulation between 24 and 72 hours of stroke onset results in achieving better functional outcomes (measured using modified Rankin Scale Scores) at 90-day follow-up (± 15 days).
CONDITIONS
Official Title
Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 85 years with a confirmed acute ischemic stroke
- NIH Stroke Scale score of 6 or higher
- Time from last known well to randomization between more than 24 and 72 hours
- Pre-stroke modified Rankin Scale score of 0 or 1
- Eligible for both thrombectomy and medical management
- Signed informed consent obtained
- Willing to comply with follow-up requirements
- Anticipated life expectancy of at least 3 months
- Proven large vessel occlusion in the internal carotid artery or M1 segment of the middle cerebral artery by MR or CT angiography
- CT ASPECTS score between 3 and 10
- Ischemic core volume 150 ml or less on CT perfusion or MR diffusion imaging
You will not qualify if you...
- Currently participating in another investigational drug or device study
- Baseline platelet count less than 100,000/µl
- Presence of intracranial tumor (except small meningioma less than 3 cm without edema or inflammation), acute brain hemorrhage, or arteriovenous malformation
- Significant brain swelling causing midline shift over 3 mm or sulcal effacement in the opposite hemisphere
- Internal carotid artery dissection that limits blood flow or aortic dissection
- Intracranial stent in the same vascular area preventing safe thrombectomy device use
- Symptomatic arterial blockages in more than one brain vessel territory
- Signs of established brain infarct, hypodensity, or cerebral edema on non-contrast CT
- CT ASPECTS score of 0 to 2
- Ischemic core volume greater than 150 ml on CT perfusion or MR diffusion imaging
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
University of Chicago
Chicago, Illinois, United States, 60637
Actively Recruiting
2
The University of Kansas Health System
Kansas City, Kansas, United States, 66103
Actively Recruiting
3
Washington University School of Medicine
St Louis, Missouri, United States, 61611
Actively Recruiting
4
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Actively Recruiting
5
Baylor University Medical Center
Dallas, Texas, United States, 75246
Actively Recruiting
6
West Virginia University
Morgantown, West Virginia, United States, 26506
Actively Recruiting
Research Team
K
Kate Rownd, MED
CONTACT
D
Deep Pujara, MBBS, MPH, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here